“Fail first” insurance mandates not just a problem for U.S. psoriasis patients

“Fail first” policies are one of the mandates imposed by some U.S. health insurers to reduce their costs. They require that people with psoriasis (and other serious diseases) try older and inferior – and often less safe – treatments before they can access the 21st century treatments that work best. Continue Reading…

Imagine knowing after 4 weeks, how a new psoriasis treatment would be working for you after 6 months…

Here’s an interesting, after-the-fact analysis from clinical trials of the biologic Ilumya (tildrakizumab-asmn), an “IL-23 inhibitor” marketed by Sun Pharma. The researchers looked at psoriasis severity scores used in clinical trials, known as PASI scores (Psoriasis Area and Severity Index), for each patient. Each patient’s score is determined before the Continue Reading…

Opioid use “substantial” among people with moderate to severe psoriasis

A recent study looked at a database of privately insured people that included about 9,000 psoriasis patients, of whom just over 2,000 were identified as having moderate to severe psoriasis. It found that about 25% of those 2,000 received opioids, compared to 16% of otherwise-comparable people without psoriasis. The figure Continue Reading…

Big Mac please, hold the broccoli
Big Mac please, hold the broccoli

Today we report a study merely as a reminder that just because it is in a scientific journal does not make it the Gospel. It was a very small study, out of Japan, based on self-reported dietary history questionnaires. (The accuracy of self-reported dietary histories is probably right up there Continue Reading…

Study finds startling rates of joint surgery in psoriatic arthritis patients

There’s a psoriatic arthritis study out of Denmark with some troubling statistics. The researchers looked at the Danish National Patient Registry from 1996 to 2017, and compared joint surgery rates between almost 12,000 psoriatic arthritis patients, and more than 100,000 people without psoriatic arthritis used as “controls” for comparison purposes. Continue Reading…

AbbVie, maker of Humira and Skyrizi, getting closer to third product to fight psoriatic disease

AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and a new biologic Skyrizi (risankizumab-rzaa), moved closer this week to having its new rheumatoid arthritis (RA) pill, Rinvoq (upadacitinib), approved for psoriatic arthritis. Rinvoq is a JAK inhibitor being studied for psoriatic arthritis as a once-daily pill. Continue Reading…

New study links itch in skin conditions (including psoriasis) to clinical depression

A new study has found that “the presence of itch in dermatological patients is significantly associated with clinical depression” and suicidal thoughts. The study, of more than 4,500 people across 13 European countries, compared four groups of people: those with dermatological (skin) diseases like psoriasis who reported having itch, those Continue Reading…

New Website … New Era

It’s a new era for psoriasis patients, with a variety of psoriasis treatments now making major improvement possible for most people with psoriasis. And it’s a new era for Psoriasis Cure Now, with a new website reflecting our mission to make sure these advances reach everyone with psoriasis and psoriatic Continue Reading…

Kim Kardashian continues to expose psoriasis to millions … usually for the best

Since first going public about her psoriasis in 2011, cultural phenomenon and wildly successful businesswoman Kim Kardashian West has given her psoriasis a recurring role in her family’s television show Keeping Up with the Kardashians (KUWTK), as well as in her social media messaging. Her every move is also chronicled Continue Reading…

More Than 20 Clinical Trials for Psoriasis and Psoriatic Arthritis Currently Recruiting Patients

Before a psoriasis treatment reaches patients, it is tested, over a period of years and at great expense, at dermatology clinics and hospitals across the United States and abroad. Volunteers are recruited to participate in these clinical trials. The formats vary; one standard trial is to compare a group of Continue Reading…

Join the Battle